Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. LeMaitre Vascular's Total Liabilities for the quarter that ended in Jun. 2026 was $220.2 Mil. LeMaitre Vascular's Total Assets for the quarter that ended in Jun. 2026 was $640.5 Mil.
Therefore, LeMaitre Vascular's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.34.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
LeMaitre Vascular Liabilities-to-Assets Related Terms
LeMaitre Vascular Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMAT vs PLSE, XRAY, ATRC: Liabilities-to-Assets Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
LeMaitre Vascular's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a Liabilities-to-Assets of 0.34 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on LeMaitre Vascular and its competitors.
Is LeMaitre Vascular's Liabilities-to-Assets too high?
LeMaitre Vascular's current Liabilities-to-Assets is 0.34. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Liabilities-to-Assets compare to PLSE and XRAY?
LeMaitre Vascular's Liabilities-to-Assets of 0.34 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on LeMaitre Vascular and its competitors. LeMaitre Vascular's current Liabilities-to-Assets is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Liabilities-to-Assets is 0.34. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Liabilities-to-Assets is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Liabilities-to-Assets: 0.34
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
